SV Health Investors’s Bicycle Therapeutics BCYC Stock Holding History

SV Health Investors’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$21.1M	Hold	907,032	–	–	65.36%	1
2022 Q2	$15.2M	Sell	907,032 -10,186	-1%	-$215K	34.74%	2
2022 Q1	$40.2M	Sell	917,218 -936	-0.1%	-$43.7K	48.61%	1
2021 Q4	$55.9M	Sell	918,154 -518,302	-36%	-$28.6M	36.13%	1
2021 Q3	$59.7M	Sell	1,436,456 -478,818	-25%	-$16.7M	29.23%	1
2021 Q2	$58.1M	Hold	1,915,274	–	–	25.33%	2
2021 Q1	$57.2M	Hold	1,915,274	–	–	21.43%	2
2020 Q4	$34.4M	Hold	1,915,274	–	–	16.56%	3
2020 Q3	$36.5M	Hold	1,915,274	–	–	18.49%	2
2020 Q2	$30.1M	Hold	1,915,274	–	–	20.91%	1
2020 Q1	$26.1M	Hold	1,915,274	–	–	21.93%	1
2019 Q4	$18.1M	Hold	1,915,274	–	–	10.94%	6
2019 Q3	$21.8M	Hold	1,915,274	–	–	15.32%	2
2019 Q2	$19.3M	Buy	+1,915,274	New	+$23.1M	12.93%	5

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SV Health Investors's BCYC Position: Q3 2022 in Review

SV Health Investors held its Bicycle Therapeutics (BCYC) position steady in Q3 2022 at 907,032 shares worth $21.1M. The position accounts for 65.36% of the portfolio, ranked #1.

SV Health Investors first reported a position in BCYC in Q2 2019 and has held it in 14 quarters since. The position peaked at $59.7M in Q3 2021. 79 funds tracked by Wall St. Rank hold BCYC as of Q3 2022.

SV Health Investors held 907,032 shares of Bicycle Therapeutics worth $21.1M as of Q3 2022.
SV Health Investors left its Bicycle Therapeutics share count unchanged in Q3 2022.
Bicycle Therapeutics made up 65.36% of SV Health Investors's portfolio in Q3 2022, its #1 holding.
SV Health Investors first reported a position in Bicycle Therapeutics in Q2 2019 and has held it in 14 quarters since.
SV Health Investors's Bicycle Therapeutics position peaked at $59.7M in Q3 2021.
79 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2022.

Based on SV Health Investors's 13F filing for Q3 2022, filed 7 Nov 2022.